Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest. (2022)
Attributed to:
Phase 1 COVID-19 Immunity - National Core Study
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.vaccine.2022.05.067
PubMed Identifier: 35718592
Publication URI: http://europepmc.org/abstract/MED/35718592
Type: Journal Article/Review
Volume: 40
Parent Publication: Vaccine
Issue: 32
ISSN: 0264-410X